This is a safety, tolerability, and pharmacokinetics study of bimatoprost in male patients with androgenetic alopecia (AGA).
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
53
DermResearch, LLC
Austin, Texas, United States
J&S Studies Inc.
College Station, Texas, United States
E&R Research Foundation
Lynchburg, Virginia, United States
Percentage of Participants with Treatment Emergent Adverse Events (TEAEs)
Time frame: 42 Days
Change from Baseline in Local Dermal Tolerability as Assessed by the Subject Using a 4-Point Scale
Time frame: Baseline, 42 Days
Maximum plasma level (Cmax) of bimatoprost and its acid metabolite
Time frame: 31 Days
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.